Home
Account
Research Tools & Data
Educate
Contribute
News
ETFs
Sectors
About
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Economic Calendar
Chart School
Tutorials
Learning Center
Submit Article
Join Blog Network
Chat Rooms
Rate Broker
Rate Software
About Us
Contact Us
Advertise With Us
Terms and Conditions
Enter Symbol
Overview
Community Research
Stock Sentiment
Whisper Estimates
Enter Estimates
Company Profile
Technical Charts
Competitors
Analyst Ratings
Analyst Estimates
Sales Estimates
Related News
Blog Articles
Press Releases
Message Board
Option Chain
Financial Ratios
Technicals
SEC Filings
Press Releases
PicksThatMove.Com Announces Investment Opinion: Hot Stocks on the Move
Marshall Edwards, Inc. Receives Nasdaq Notice of Minimum Bid Price Non-Compliance
Marshall Edwards Licenses the Investigational Anti-Cancer Compound NV-128 From Novogen Limited
Researchers Discover That Phenoxodiol Kills Rapidly Proliferating T-Cells
Independent Data Monitoring Committee Reviews Marshall Edwards, Inc.'s Arrangements for Data Analysis of the Ovature Trial
Marshall Edwards, Inc., to Undertake Analysis of Ovature Trial
Board Changes at Novogen Limited Announced - Mar 23 2009 12:55PM
Board Changes at Novogen Limited Announced - Mar 23 2009 11:02AM
Biotech Analyst Joins Board of Directors of Marshall Edwards, Inc.
Novogen's NV-128 Targets the mTOR Pathway to Induce Cell Death in Epithelial Ovarian Cancer Stem Cells
Triphendiol Safety Data Clears the Way for Compound to Be Studied Further in the Treatment of Pancreatic Cancer
Yale Researchers Present Results of Phase II Phenoxodiol Clinical Trial in Prostate Cancer Patients at ASCO 2009 Genitourinary Cancers Symposium
Perceptive Informatics Establishes Alliance With AG Mednet to Bring Greater Efficiency and Quality to Medical Imaging-Based Trials
Marshall Edwards, Inc. to Present at the 27th Annual JPMorgan Healthcare Conference
Marshall Edwards, Inc. Granted IND for Triphendiol
Marshall Edwards, Inc. Announces Resignation of Stephen Breckenridge From Board of Directors and Appointment of William Rueckert as Chairman of Audit Committee
Marshall Edwards, Inc. Files IND Application for Triphendiol
Independent Data Monitoring Committee Recommends Marshall Edwards, Inc.'s OVATURE Trial Continue - Nov 13 2008 8:20AM
Independent Data Monitoring Committee Recommends Marshall Edwards, Inc.'s OVATURE Trial Continue - Nov 12 2008 8:20AM
Marshall Edwards' Phenoxodiol and Novogen's NV-128 Display Divergent Mechanisms of Action but Potent Synergistic Anti-Cancer Activity When Used in Combination
Marshall Edwards, Inc. to Present at the Canaccord Adams 28th Annual Global Growth Conference
Novogen Raises A$5.5m for Investment in Marshall Edwards
Marshall Edwards, Inc. Raises $10,000,000 in Public Offering
Marshall Edwards, Inc. Joins Russell 3000(R) Index
Novogen Signs Spanish Patent License With Laboratorios Casen-Fleet
Independent Data Monitoring Committee Recommends Marshall Edwards, Inc.'s OVATURE Trial Continue - Jun 9 2008 8:05AM
Clinical Phase I Study Report of Marshall Edwards' Compound Triphendiol to Be Reported in ASCO Proceedings - May 27 2008 12:55AM
Extended Accrual Time and Decreased Sample Size for OVATURE, a Multinational Phase III Clinical Study for Women With Recurrent Ovarian Cancer - Jun 2 2008 12:29AM
Marshall Edwards, Inc.'s Investigational Drug Triphendiol (NV-196) Demonstrates Potent Activity Against Biliary Cancers
Fundamental data is provided by
Zacks Investment Research
, market data is provided by
AlphaTrade.
, and Commentary and Press Releases provided by
Quotemedia
